SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
The MarketWatch News Department was not involved in the creation of this content. Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback